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ABSTRAK
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bermakna. Penyebab kematian langsung pada kolangitis akut adalah sepsis yang berkembang menjadi syok 
yang ireversibel dan kegagalan multi organ. Faktor predisposisi tersering adalah batu empedu dan riwayat 
manipulasi traktus biliaris. ?n?eksi bilier dan obstruksi bilier adalah dua pato?siologi utama kolangitis akut. 
?akteri gram negati? sering ditemukan pada kultur ?airan empedu dan darah. Penyebab utama obstruksi 
bilier adalah batu empedu. 
?rias ?har?ot yang sering digunakan untuk mendiagnosis kolangitis akut memiliki banyak keterbatasan 
dan gejala klinis dari penyakit memiliki gambaran yang luas yang berkisar dari gejala ringan sampai penyakit 
berat yang mengan?am nyawa. ?leh karena itu? penggunaan Panduan ?okyo yang terbaru ?????? penting 
digunakan untuk mendiagnosis penyakit dan menilai keparahan. ?riteria diagnostik ???? berdasarkan 
adanya in?amasi sistemik? kolestasis? dan bukti dari pemeriksaan pen?itraan terhadap traktus bilier. ?erapi 
yang dini disesuaikan berdasarkan derajat keparahan yang ternilai dengan ????. ?erapi awal terdiri dari 
penggantian ?airan yang adekuat? pengendalian hemodinamik? kompensasi elektrolit? pemberian antibiotik 
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intravena? dan pemberian anti nyeri intravena. ?erapi de?niti? yang berhubungan dengan pato?siologi penyakit 
adalah drainase bilier dan pemberian antibiotik
Kata kunci: kolangtis akut? Panduan ?okyo? traktus biliaris? obstruksi biliar? batu empedu? trias ?har?ot?s 
INTRODUCTION
Acute cholangitis (AC) is one of the biliary tract 
emergencies in the spectrum of acute biliary infection 
with high morbidity and mortality rates; thus, it needs 
straightforward diagnostic evaluation and immediate 
treatment initiation. Acute cholangitis is an acute 
?????????? ?????????????????????????????????????????????
tract.1,2 Clinical presentation of AC ranges from mild 
symptoms to severe life-threatening with septic shock 
conducting rapidly to death.2? ??? ???????????????????
described the Charcot’s triad – a clinical pattern with 
intermittent fever accompanied by chills and rigor, 
right upper abdominal pain and jaundice. About 50-
70% of the patients with acute cholangitis present with 
Charcot‘s triad. Later, in 1959, Reynolds and Dragan 
described a syndrome consisting of fever, jaundice, 
abdominal pain, altered mental status (confusion or 
lethargy), and shock. They called it Reynold’s pentad 
with the underlying pathology of acute obstructive 
cholangitis.1-4 Longmire described these two conditions 
as acute suppurative cholangitis and acute obstructive 
suppurative cholangitis. They are associated with 
increased morbidity and mortality.1
The most common cause of acute cholangitis is 
common bile duct stone (choledocholithiasis).2 Other 
causes of AC are malignancy, benign strictures, and 
interventions to the biliary ducts that cause biliary 
obstruction.3 Mortality rate in severe cholangitis 
??????????????????? ??????????????????? ???????????
Advances in intensive care, antibiotic regimens 
and biliary drainage techniques have dramatically 
improved the mortality rate of more than 50% prior to 
the 1970s to less than 10% in the 1980s.2 
There is a wide spectrum of disease courses 
in acute bacterial cholangitis,4 Patients with acute 
cholangitis may present with any severity ranging 
from self-limiting to severe and/or potentially life-
threatening diseases. Most cases respond to initial 
medical treatment consisting of general supportive 
therapy and intravenous antimicrobial therapy As a 
therapeutic procedure for severe cases or to prevent 
increased severity, decompression of the biliary tract 
(i.e., biliary tract drainage) is necessary.5 Recent 
advances in and diffusion of endoscopic biliary tract 
drainage along with the administration of antimicrobial 
agents have contributed to the decrease in the number 
of deaths due to acute cholangitis. However, it remains 
a life-threatening disease if the timing of biliary tract 
drainage has been missed.3,5 Therefore, immediate 
and precise judgment of severity is of the utmost 
importance. The most well-known diagnostic criteria 
and severity assessment that has been used for years is 
Tokyo Guidelines (TG) with their most updated Tokyo 
Guidelines 2018 (TG18).
Epidemiology
The incidence of acute cholangitis ranges from 0.3 
to 1.6% with a proportion of severe cholangitis that 
reaches 12.3%.2 The most common characteristics that 
predispose patients to the development of cholangitis 
are bile duct stones and previous manipulation of the 
biliary tree, including stenting and biliary surgery 
resulting in stricture. Incidence of cholangitis is 
associated with prevalence of cholelithiasis.6 Gallstones 
are found in 10% to 15% of the white population in 
the United States. It is much more prevalent in native 
Americans (60%-70%) and Hispanics but less common 
in Asians and African Americans. Many patients get 
admitted to the hospital with gallstone disease and 6% 
to 9% of them are diagnosed with acute cholangitis.7 
Gallstones are estimated to be responsible for 
approximately 65% of cholangitis cases, followed by 
24% as a result of malignant stenosis, 4% caused by 
benign stenosis, 3% a result of sclerosing cholangitis, 
and 1% caused by other or unknown factors. Of those 
with asymptomatic gallbladder stones, approximately 
0.6%–1.3% will go on to develop cholangitis over a 10-
year period.6 Males and females are equally affected. 
The average age of patients presenting with acute 
cholangitis is 50 to 60 years. Less than 200.000 cases 
of cholangitis occur per year in the United States.7 
There is no report about acute cholangitis incidence 
in Indonesia.
The proportion of cases diagnosed as severe 
(grade III) according to the Tokyo Guidelines 07 
(TG07) severity assessment criteria was 12.3 %.2 In 
a large, multicenter case series study on patients with 
Acute Cholangitis conducted in Japan and Taiwan, 
application of the TG13 severity grading criteria to 
the case series yielded 1,521 patients with Grade III 
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(25.1%), 2,019 patients with Grade II (33.3%), and 
2,523 patients with Grade I (41.6%).8
Pathophysiology
Acute cholangitis is characterized by acute 
???????????? ???? ?????????? ??? ???? ????? ????? ???????
with increased bacterial loads (biliary infection) and 
high intraductal pressure levels (biliary obstruction) 
favoring bacterial and endotoxin translocation into 
the vascular and lymphatic drainage (concept of 
cholangiovenous and cholangiolymphatic reflux, 
respectively).4 
Bacteria primarily enter the biliary system by 
ascending from the duodenum into the common 
hepatopancreatic duct (hence the terms ascending and 
suppurative cholangitis).6,9 The portal venous system 
and the periportal lymphatic system are also potential 
routes of entry, which is thought to occur less frequently. 
The mere presence of bacteria in the biliary system, 
????????????????????????????????????????????????????????????
symptoms without coexistent obstruction due to effective 
?????????????????????????????????????????????????????????
immunoglobulin (Ig) A secretion protecting Kupffer cell 
function and integrity of biliary tight junctions.4  
Intracholedochal (intrabiliary) pressure is the most 
important factor.3 The critical threshold of intrabiliary 
pressure has been determined to be >20 cm H2O 
(normal value: 7–14 cm H2O).4 If the pressure exceeds 
25 cm H2O, which is the critical value, hepatic 
defence mechanisms against infection are disrupted 
and infection spreads into the intrahepatic canalicules, 
??????????????????????????????????????????????????
access to the hepatic veins and lymphatics, resulting 
in bacteriemia and endotoxinemia.3,7 
???????? ?????? ????????? ???????? ??? ????????????
mediators like tumor necrosis factor (TNF), soluble 
TNF receptors, interleukin (IL)-1, IL-6 and IL-10 
leads to profound hemodynamic compromise.  In 
conjunction with an increased permeability of the 
?????????????????????????????????????????????????????????
potentially fatal complications such as biliary sepsis 
and hepatic abscess.4 Sepsis is common in the case of 
suppurative infections. 
Clinical Presentation
Classically, patients present with high fever 
persisting for more than 24 h, abdominal pain and 
jaundice (Charcot’s triad or hepatic fever). The 
right upper quadrant abdominal pain is generally 
mild.7??????????????? ?????? ?????? ?????? ????? ????????
of hypotension and altered mental status (Reynold’s 
pentad) are seen in only 5%–7% of cases, but typically 
represent more severe disease when present.6,7
Charcot’s triad has low sensitivity (26.4%) and 
????? ??????????? ?????????????????? ???? ????????? ???
Charcot’s triad is suggestive of acute cholangitis, it 
is not diagnostic. However, some patients may not 
manifest all the symptoms and signs.
Imaging Findings
Imaging evaluation of the hepatobiliary system 
has the primary role in diagnostic modalities, staging 
and management for cholangitis.9 However, even 
though new technologies and knowledge are steadily 
accumulating, there is no way to directly diagnose 
Acute Cholangitis based on imaging findings.8 
Diagnostic imaging is considered as a method to directly 
identify biliary stenosis/blockage that can cause Acute 
Cholangitis or to describe cholangiectasis that can be 
??????????????????????????????????????????????????????
???????? ???????????????????????????????????????????
include abdominal ultrasound, computed tomography 
(CT), and magnetic resonance imaging (MRI)/magnetic 
resonance cholangiopancreatography (MRCP), 
whereas simple X-rays are not suited to diagnose. 
Endoscopic retrograde cholangiopancreatography is 
performed for the purposes of treatment (drainage), but 
???????????????????????????????????????????????????????8
Diagnosis
Acute cholangitis (AC) has been diagnosed on the 
basis of Charcot’s triad, which depends on clinical 
signs. To compensate for the low sensitivity of 
Charcot’s triad, the Tokyo Guideline 2007 (TG07) 
diagnostic criteria were based on Charcot’s triad 
?????????????????????????????????????????????????????
however, this still did not provide good sensitivity. In 
the updated TG13 guidelines, the Tokyo Guidelines 
Revision Committee conducted joint research at 
multiple sites which had exhibited good sensitivity 
????????????????????????????????????????????????????
rate (38.8%) of false positives for acute cholecystitis. 
The TG13 diagnostic criteria is being used again in 
recently updated TG18 (Figure 1).8
Severity Assessment
?????????????????????????????????????????????????????
because there is a wide spectrum of disease in acute 
cholangitis, ranging from self-limiting to life-threatening 
with the need to tailor treatment accordingly. 
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???????????????????????
A-1. Fever and/or shaking chills
??????????????????????????????????????????????????????
B. Cholestasis
B-1. Jaundice
B-2. Laboratory data: abnormal liver function tests
C. Imaging
C-1. Biliary dilatation
C-2. Evidence of the etiology on imaging (stricture, stone, stent etc.)
Suspected diagnosis: one item in A + one item in either B or C
?????????????????????????????????????????????????????????????????
Note:
???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
B-2: Increased serum ALP, r-GTP (GGT), AST, and ALT levels. 
Other factors which are helpful in diagnosis of acute cholangitis include abdominal pain (right upper quadrant or upper abdominal) and 
a history of biliary disease such as gallstones, previous biliary procedures, and placement of a biliary stent. In acute hepatitis, marked 
??????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????
Thresholds:
A-1 Fever BT >38°C
????????????????????????????????????
WBC count (91,000/lL) <4 or >10
??????????????
?????????????????????????????
B-2 Abnormal liver
function tests
ALP (IU) >1.5 9 STDa
cGTP (IU) >1.5 9 STDa
AST (IU) >1.5 9 STDa
ALT (IU) >1.5 9 STDa
Figure 1. TG18/TG13 diagnostic criteria for acute cholangitis8
Grade III (severe) acute cholangitis
?????????????????????????????????????????????????????????????????????????????????????????
onset of dysfunction at least in any one of the following organs/systems:
1. ????????????????????????????????????????????????????????????????????????????????
any dose of norepinephrine
2. Neurological dysfunction: disturbance of consciousness
3. Respiratory dysfunction: PaO2/FiO2 ratio <300
4. Renal dysfunction: oliguria, serum creatinine >2.0 mg/dL
5. Hepatic dysfunction: PT-INR >1.5
6. Hematological dysfunction: platelet count <100,000/mm3
Grade II (moderate) acute cholangitis
“Grade II” acute cholangitis is associated with any two of the following conditions:
1. Abnormal WBC count (>12,000/mm3, <4,000/mm3)
?????????????????????
??????????????????????
????????????????????????????????????????????????
5. Hypoalbuminemia (<STDa90.7)
Grade I (mild) acute cholangitis
“Grade I” acute cholangitis does not meet the criteria of “Grade III (severe)” or “Grade 
II (moderate)” acute cholangitis at initial diagnosis.
Early diagnosis, early biliary drainage and/
or treatment for etiology, and antimicrobial 
administration are fundamental treatment for 
?????? ???????????? ?????????? ???? ????? ??????? ????
(severe)” and “Grade II (moderate)” but also 
“Grade I (mild)”.
Therefore, it is recommended that patients with 
acute cholangitis who do not respond to the 
initial medical treatment (general supportive 
care and antimicrobial therapy) undergo early 
biliary drainage or treatment for etiology (see 
?????????
Figure 2. TG18/TG13 severity assessment criteria for acute cholangitis8
The TG13 severity grading criteria are recommended 
to be used as the TG18 criteria because patients whose 
prognosis can potentially be improved by early biliary 
????????????? ???????????? ?? ???????????????????????????? ??8
The most recent study has demonstrated that 
procalcitonin predicts severe acute cholangitis with 
better accuracy than conventional biomarkers (WBC 
and CRP), regardless of the cause. The optimal cut off 
value for procalcitonin for prediction of severe acute 
cholangitis was 2.2 ng/ ml. The study suggested potential 
????????????????????????????????????????????????????????
?????? ???????????? ??? ??????????? ??????? ?????????????????
patients in whom biliary drainage is indicated.10
Treatment 
Patients with cholangitis should be managed at the 
hospital, as this is considered as an emergent condition. 
?????????????????????????????????????? ?????????????????
due to infection and obstruction of the biliary system, 
we have to treat both aspects.7
Initial Treatment 
For all patients with early recognition of cholangitis, 
?????????????????????????????????????????????????????? ????
replacement, electrolyte compensation, intravenous 
administration of analgesics and full-dose antimicrobial 
agents is started, with careful monitoring of blood 
pressure, heart rate, and urine volume.6,7,11,12 Analgesics 
should be administered proactively at an early stage. 
Opioid analgesics such as morphine hydrochloride 
and other similar types of drug (such as non-opioid 
analgesics and pentazocine) cause the sphincter of Oddi 
to contract, which may elevate biliary pressure, and must 
therefore be administered with caution.11 
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In the case of serious deterioration, such as the 
appearance of shock (hypotension), disturbance of 
consciousness, acute dyspnea, acute renal dysfunction, 
hepatic dysfunction, or disseminated intravascular 
coagulation (DIC) (reduced platelet count), emergency 
biliary drainage should be considered alongside 
appropriate organ support and respiratory/circulatory 
??????????? ?????? ??? ?????????? ????????????? ?????????
intubation, and the use of hypertensive agents).11
Antibiotic 
Once the microorganism culture and sensitivity 
testing results are available, initial broad-spectrum 
antimicrobial therapy is revised to a more targeted 
narrow spectrum therapy.1 For patients with septic 
shock, appropriate antimicrobial therapy should 
be administered within an hour. For less acute ill 
patients, therapy should be administered within 6 h of 
diagnosis.6,7,13 The roles of antimicrobial therapy for 
acute cholangitis is to allow patients to have elective 
drainage procedures other than emergency.13
Antimicrobial agents appropriate for use as 
empirical therapy for community-acquired and 
healthcare-associated infections are provided in table 
3, table 4, and table 5. In the TG18, the duration of 
therapy for patients with acute cholangitis is for 4 
to 7 days once the source of infection is controlled 
by integrating the above studies and expert opinion. 
When bacteremia with Gram-positive bacteria such as 
Enterococcus spp. and Streptococcus spp. is present, 
it is prudent to offer antimicrobial therapy for 2 
weeks since these organisms are well-known to cause 
infective endocarditis.13 Once susceptibility testing 
results of causative microorganisms are available, 
specific therapy (or definitive therapy) should be 
offered. This process is called de-escalation13 
Algorithm for the Management of Acute Cholangitis 
After severity has been assessed and the patient’s 
general status has been evaluated, a treatment strategy 
??????????????????????????????????????????????????????
3) for the management of acute cholangitis or acute, 
and treatment should immediately be provided.11 Acute 
cholangitis should be treated in accordance with its 
severity.  The two key pillars of the treatment of acute 
cholangitis are antibiotics and biliary drainage. If blood 
culture has not been performed as part of the initial 
response, it should be carried out before antibiotic 
administration. If biliary drainage is performed, bile 
samples must always be sent for culture.
Treatment according to grade, response, and according to need for addional theraphy
* Performance of a blood culture shuold be taken into consideration befeore initiation of administration of antibiotics. A bile culture 
should be performed during biliary drainage.
? Principle of treatment for acute cholangitis consists of antimicrobial administration and biliary drainage including treatment for 
etiology. For patient with choledocholithiasis, treatment for etiology might be performed stimultaneously, if possible, with biliary 
drainage.
Figure 3. TG18 ?o?chart for the management of acute cholangitis11
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Grade I (mild acute cholangitis)
Grade I or mild acute cholangitis is defined 
as cholangitis which does not meet the TG18 
severity assessment criteria for moderate or severe 
cholangitis. In most cases initial treatment including 
antibiotics is sufficient, and most patients do not 
require biliary drainage. However, biliary drainage 
should be considered immediately if a patient does 
not respond to initial treatment within 24 hours.11-12 
Endoscopic sphincterotomy (EST) and subsequent 
choledocholithotomy may be performed at the same 
time as biliary drainage. Postoperative cholangitis 
usually improves with antibiotic treatment alone, and 
biliary drainage is not usually required.11 
Grade II (moderate acute cholangitis)
Moderate acute cholangitis requires early biliary 
drainage. In the TG18 severity assessment criteria, 
moderate cholangitis is assessed if at least two of 
???? ?????????????? ????????? ??????????????????????
??????????????????????????????????????????????????????
?????????? ? ? ?????? ?????????? ?????????????? ?? ??????
value 9 0.73 g/dL). Early endoscopic or percutaneous 
transhepatic biliary drainage is indicated.12 If early 
drainage cannot be performed because of a lack of 
facilities or skilled personnel, consider transferring 
the patient.12
If the underlying etiology requires treatment, 
this should be provided after the patient’s general 
Table 2. Antimicrobial recommendations for grade II (moderate) 
acute cholangitis13
Antimicrobial class Antimicrobial agents
Penicillin-based therapy Piperacillin/tazobactam
Cephalosporin-based therapy Ceftriaxone,
or Cefotaxime,
or Cefepime,
or Cefozopran,
or Ceftazidime
±Metronidazole*
Cefoperazone/sulbactam
Carbapenem-based therapy ertapenem
Fluoroquinolone-based therapy ??????????????????????????
???????????
± Metronidazole*
???????????
*Anti-anaerobic therapy, including use of metronidazole, tinidazole, or 
clindamycin, is warranted if a biliary-enteric anastomosis is present. The 
carbapenems, piperacillin/tazobactam, ampicillin/sulbactam, cefmetazole, 
?????????????????????????????????????????????????????????????????????????????
activity for this situation
Table 1. Antimicrobial recommendations for grade I (mild) acute 
cholangitis13
Antimicrobial class Antimicrobial agents
Penicillin-based therapy Ampicillin/sulbactam* is not 
recommended
if > 20% resistance rate
C e p h a l o s p o r i n - b a s e d 
therapy
Cefazolin**
or Cefotiam**
or Cefuroxime**,
or Ceftriaxone,
or Cefotaxime**
±Metronidazole***
Cefmetazole**, Cefoxitin**,
Flomoxef**, Cefoperazone/
sulbactam
Carbapenem-based therapy ertapenem
Fluoroquinolone-based 
therapy
??????????????????????????
???????????
± Metronidazole***
???????????
*Ampicillin/sulbactam has little activity left against Escherichia coli. It is 
removed from the North American guidelines
**Local antimicrobial susceptibility patterns (antibiogram) should be considered 
for use
***Anti-anaerobic therapy, including use of metronidazole, tinidazole, or 
clindamycin, is warranted if a biliary-enteric anastomosis is present. The 
carbapenems, piperacillin/tazobactam, ampicilli n/ sulbactam, cefmetazole, 
?????????????????????????????????????????????????????????????????????????????
activity for this situation
condition has improved, and EST and subsequent. 
choledocholithotomy may be performed together 
with biliary drainage. Cholecystectomy should be 
performed for cholecystolithiasis after the acute 
cholangitis has resolved.11 
Grade III (severe acute cholangitis)
Severe acute cholangitis is cholangitis with sepsis-
induced organ damage. In the TG18 severity assessment 
criteria, severe cholangitis is assessed if any one of the 
following criteria is met: cardiovascular dysfunction 
????????????????????????????????????????????????????
noradrenaline), neurological dysfunction (disturbance 
of consciousness), respiratory dysfunction (PaO2/
??????????? ????????????????????????????????????????????
creatinine > 2.0 mg/dL), hepatic dysfunction (PT-INR 
??????????????????????????????????????????????? ?????????
mm3). As the patient’s condition may deteriorate 
rapidly, a swift response is essential including 
appropriate respiratory/circulatory management 
???????????????????????????????????????????????????????
Table 3. Antimicrobial recommendations for grade III (severe) 
acute cholangitis and healthcare-associated cholangitis13
Antimicrobial class Antimicrobial agents
Penicillin-based therapy Piperacillin/tazobactam
C e p h a l o s p o r i n - b a s e d 
therapy
Cefepime,
or Ceftazidime,
or Cefozopran
± Metronidazole*
Carbapenem-based therapy Imipenem/cilastatin, Meropenem,
Doripenem, Ertapenem
Monobactam-based therapy Aztreonam  Metronidazole
*Anti-anaerobic therapy, including use of metronidazole, tinidazole, or 
clindamycin, is warranted if a biliary-enteric anastomosis is present. The 
carbapenems, piperacillin/tazobactam, ampicillin/sulbactam, cefmetazole, 
?????????????????????????????????????????????????????????????????????????????
activity for this situation
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and the use of hypertensive agents). Endoscopic or 
percutaneous transhepatic biliary drainage should 
be performed as soon as possible after the patient’s 
condition has been improved by initial treatment and 
respiratory/ circulatory management. If treatment 
for the underlying etiology is required, this should 
be provided after the patient’s general status has 
improved.11
Indications and Techniques of Biliary Drainage
In the recently updated TG18, biliary drainage is 
recommended for acute cholangitis regardless of the 
degree of severity except in some cases of mild acute 
cholangitis in which antibiotics and general supportive 
care are effective.13
Endoscopic Transpapillary biliary Drainage (ETBD)
Endoscopic transpapillary biliary drainage should be 
?????????????????? ???-line drainage procedure because 
of its less invasiveness and lower risk of adverse events 
than other drainage techniques despite the risk of 
post-endoscopic retrograde cholangiopancreatography 
(ERCP) pancreatitis.14,15 This technique is gold 
standard treatment for acute cholangitis irrespective 
of the benign or malignant nature of the primary 
disease14. Endoscopic transpapillary biliary drainage 
is divided into two types: endoscopic nasobiliary 
drainage (ENBD) for external drainage and endoscopic 
biliary stenting (EBS) for internal drainage. Basically, 
both types of endoscopic biliary drainage can be 
performed in all forms of acute cholangitis. In the 
case of biliary drainage for acute cholangitis therapy, 
a precise endoscopic technique is mandatory because 
long and unsuccessful procedures may lead to serious 
complications in critically ill patients. 
In the updated TG18, we suggest that either ENBD 
or EBS may be considered for biliary drainage by 
procedure according to the cause of the cholangitis, 
bile property, and patient’s preference.
Endoscopic Nasobiliary Drainage
Endoscopic nasobiliary drainage procedures are 
described in detail in TG07. In brief, after selective 
biliary cannulation, a 5-Fr to 7-Fr nasobiliary tube is 
placed in the bile duct as an external drainage over 
the guidewire.
Endoscopic Biliary Stenting
The EBS procedure is also described in detail in 
the previous clinical practice guidelines. In brief, 
after selective biliary cannulation, a 7-Fr to 10-Fr 
plastic stent is placed in the bile duct as an internal 
drainage over the guidewire.14 There are two different 
stent shapes, a straight type and a double pigtail type. 
???? ????????? ????????? ?? ???????????????? ?? ??????????
????????????????????????????????????????????????????
(Tannenbaum type) on both sides. The double pigtail 
type prevents inward and outward stent migration. 
To our knowledge, there is currently no comparative 
study between the straight type and pigtail type stents. 
Therefore, either stent can be selected according to the 
endoscopist’s preference.
The internal drainage by endoscopic transpapillary 
biliary drainage produces less pain after the procedures 
than that of the external drainage by percutaneous 
transhepatic biliary drainage (PTBD), also known 
as percutaneous transhepatic cholangial drainage 
(PTCD).14 PTCD places more burden on cosmetic 
problems, skin inflammation, and bile leakage, 
affecting the patient's quality of life. A single treatment 
session for a bile duct stone is possible with the 
endoscopic transpapillary approach, making shorter 
length of hospitalization.
Percutaneous Transhepatic Cholangial Drainage 
(PTCD)
PTCD is a useful alternative drainage procedure to 
endoscopic transpapillary biliary drainage approach 
and being indicated to the patients with an inaccessible 
papilla due to upper gastrointestinal tract obstruction, 
or when skilled pancreaticobiliary endoscopists are 
not available in the institution.14 Furthermore, PTCD 
can be used as a salvage therapy when conventional 
endoscopic transpapillary drainage has failed owing 
??? ????????? ?????????? ???????? ???????????????????????
endoscopic ultrasound-guided biliary drainage (EUS-
BD) has been developed and reported as a novel 
useful alternative drainage technique when standard 
endoscopic transpapillary drainage has failed.14
PTCD is performed with ultrasonography-guided 
transhepatic puncture of the intrahepatic bile duct is 
initially performed using an 18-G to 22-G needle. 
????????????????????????????????????????????????????
advanced into the bile duct. Finally, a 7-Fr to 10-Fr 
??????????????????????????????????????????????????????
control over the guidewire. Puncture using a small-
gauge (22-G) needle is safer in patients without biliary 
dilation than in patients with biliary dilation.14,15
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Surgical Drainage
Open drainage for decompression of the bile duct 
is performed as a surgical intervention. When surgical 
drainage in critically ill patients with bile duct stones 
is performed, prolonged operations should be avoided 
and simple procedures, such as T-tube placement 
without choledocholithotomy, are recommended. At 
present, surgical drainage is extremely rare because of 
the widespread use of endoscopic drainage or PTCD 
for acute cholangitis therapy.14
Prognosis
The prognosis depends on the timing of 
biliary drainage, administration of antibiotics and 
comorbidities of the patient. Early biliary drainage 
leads to rapid clinical improvement. But, if biliary 
drainage is delayed, patients can deteriorate quickly 
and die. The overall mortality acute cholangitis is 
less than 10% after biliary drainage.  Poor prognostic 
factors in the setting of acute cholangitis include old 
age, high fever, leukocytosis, hyperbilirubinemia and 
hypoalbuminemia. Patients with comorbidities like 
cirrhosis, malignancy, liver abscess and coagulopathy 
also carry poor prognosis. 
CONCLUSION
Prompt clinical recognition, accurate diagnostic 
workup and severity assessment including adequate 
laboratory assessment and etiology oriented imaging 
are critical steps in the management of acute 
cholangitis. Treatment is directed at the two major 
interrelated pathophysiologic components, i.e. 
bacterial infection (immediate antimicrobial therapy) 
and bile duct obstruction (biliary drainage). 
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